Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy

[1]  Radhe Mohan,et al.  Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[2]  P. Ganz,et al.  Inflammatory Biomarkers and Fatigue during Radiation Therapy for Breast and Prostate Cancer , 2009, Clinical Cancer Research.

[3]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[4]  C. Cleeland,et al.  Serum interleukin‐6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation , 2008, Cancer.

[5]  Alberto Mantovani,et al.  Cytokines as a key component of cancer-related inflammation. , 2008, Cytokine.

[6]  E. Chow,et al.  Symptom clusters in cancer patients: a review of the literature , 2007, Current oncology.

[7]  C. Cleeland.  Symptom burden: multiple symptoms and their impact as patient-reported outcomes. , 2007, Journal of the National Cancer Institute. Monographs.

[8]  L. Natarajan,et al.  The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review , 2007, Brain, Behavior, and Immunity.

[9]  C. Gotay.  Advancing Health Outcomes Research Methods and Clinical Applications , 2006, Quality of Life Research.

[10]  Joe Y. Chang,et al.  Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Mellar P. Davis,et al.  Cancer symptom assessment instruments: a systematic review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Nishimura,et al.  Phase I/II study of weekly docetaxel dose escalation in combination with fixed weekly cisplatin and concurrent thoracic radiotherapy in locally advanced non-small cell lung cancer , 2006, Cancer Chemotherapy and Pharmacology.

[13]  M. Dewhirst,et al.  Cytokine profiling for prediction of symptomatic radiation-induced lung injury. , 2005, International journal of radiation oncology, biology, physics.

[14]  G. Morrow,et al.  Occurrence, severity, and longitudinal course of twelve common symptoms in 1129 consecutive patients during radiotherapy for cancer. , 2005, Journal of pain and symptom management.

[15]  M. Albitar,et al.  Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome , 2005, Cancer.

[16]  R. Dantzer,et al.  A Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms , 2004, Neuroimmunomodulation.

[17]  N. Willich,et al.  Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  J. Unützer,et al.  National Institutes of Health State-of-the-Science Conference Statement: Symptom Management in Cancer: Pain, Depression, and Fatigue, July 15-17, 2002. , 2003, Journal of the National Cancer Institute.

[19]  J. Denham,et al.  Fatigue during breast radiotherapy and its relationship to biological factors. , 2004, International journal of radiation oncology, biology, physics.

[20]  Issam El-Naqa,et al.  Dosimetric correlates for acute esophagitis in patients treated with radiotherapy for lung carcinoma. , 2004, International journal of radiation oncology, biology, physics.

[21]  J. Rossi,et al.  Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  R. Dantzer,et al.  Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? , 2003, Cancer.

[23]  N. Willich,et al.  Modulation of radiation-induced tumour necrosis factor α (TNF-α) expression in the lung tissue by pentoxifylline , 2002 .

[24]  Patricia A. Ganz,et al.  Fatigue and Proinflammatory Cytokine Activity in Breast Cancer Survivors , 2002, Psychosomatic medicine.

[25]  S. Paul,et al.  Symptom clusters and their effect on the functional status of patients with cancer. , 2001, Oncology nursing forum.

[26]  R. Dantzer.  Cytokine-Induced Sickness Behavior: Where Do We Stand? , 2001, Brain, Behavior, and Immunity.

[27]  C. Cleeland.  Cancer-related symptoms. , 2000, Seminars in radiation oncology.

[28]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[29]  M. Barcellos-Hoff,et al.  How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. , 1998, Radiation research.

[30]  R. Kurzrock,et al.  Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma , 1997, Annals of Internal Medicine.

[31]  R. Littell.  SAS System for Mixed Models , 1996 .

[32]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[33]  D. Miles,et al.  Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2. , 1992, British Journal of Cancer.

[34]  S. Joel,et al.  Measuring cytokine levels in blood. Importance of anticoagulants, processing, and storage conditions. , 1992, Journal of immunological methods.

[35]  R. Littell.  ANALYSIS OF REPEATED MEASURES DATA , 1990 .

[36]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[37]  P. Buckley,et al.  Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With Cancer , 2009 .

[38]  L. Nail,et al.  Symptom cluster research: conceptual, design, measurement, and analysis issues. , 2006, Journal of pain and symptom management.

[39]  N. Willich,et al.  Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. , 2002, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[40]  C. Cleeland,et al.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. , 2000, Cancer.